Format

Send to

Choose Destination
Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):47-53. doi: 10.1097/WAD.0b013e3181610fea.

Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.

Author information

1
Department of Neurology, School of Medicine, Athens National University, Eginition Hospital, Athens, Greece. ekapaki@med.uoa.gr

Abstract

BACKGROUND:

Cerebrospinal fluid (CSF) biomarkers have been increasingly studied in dementia clinical and differential diagnosis.

METHODS:

We assessed levels of total tau protein (tauT), tau phosphorylated at threonine 181 (tau P-181), and beta-amyloid1-42 (A beta 42) in 34 patients with frontotemporal lobar degeneration (FTLD), 76 Alzheimer disease (AD) cases, and 93 controls (CTRL). Double sandwich enzyme-linked immunosorbent assays (Innogenetics) were used for measurements.

RESULTS:

Total tau was significantly increased and A beta 42 decreased in FTLD and AD patients as compared with CTRL. CSF tau P-181 levels were significantly increased only in AD. The tauT/A beta 42 ratio successfully discriminated FTLD from CTRL with a 86.7% specificity and 80.6% sensitivity, whereas the tauT alone was more specific (95.7%) but less sensitive (64.75%). For the discrimination of FTLD from AD, tauT/A beta 42 ratio was better (90.3% sensitivity and 64.5% specificity) compared with the other biomarkers alone or in combination, whereas tau P-181 was less sensitive but more specific (68.4% and 85.7%, respectively). Subtype analysis revealed that the most AD-like profile of biomarkers were observed in FTLD with motor neuron signs, whereas the most non-AD profile were observed in patients with primary progressive aphasia.

CONCLUSIONS:

Combined analysis of CSF biomarkers may be useful for the best possible antemortem discrimination of FTLD from AD.

PMID:
18317246
DOI:
10.1097/WAD.0b013e3181610fea
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center